Sio Gene Therapies Balance Sheet Health
Financial Health criteria checks 4/6
Sio Gene Therapies has a total shareholder equity of $45.1M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $47.3M and $2.2M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$46.13m |
| Equity | US$45.12m |
| Total liabilities | US$2.15m |
| Total assets | US$47.27m |
Recent financial health updates
Can Sio Gene Therapies (NASDAQ:SIOX) Afford To Invest In Growth?
Oct 19
Here's Why We're A Bit Worried About Sio Gene Therapies' (NASDAQ:SIOX) Cash Burn Situation
Jun 27We're Hopeful That Sio Gene Therapies (NASDAQ:SIOX) Will Use Its Cash Wisely
Sep 28We Think Sio Gene Therapies (NASDAQ:SIOX) Needs To Drive Business Growth Carefully
May 07Recent updates
Can Sio Gene Therapies (NASDAQ:SIOX) Afford To Invest In Growth?
Oct 19Here's Why We're A Bit Worried About Sio Gene Therapies' (NASDAQ:SIOX) Cash Burn Situation
Jun 27My Favorite Stock For 2022: Sio Gene Therapies
Dec 27Sio Gene Therapies: Excellent Data And News Obscured By Officer's Departure
Oct 25We're Hopeful That Sio Gene Therapies (NASDAQ:SIOX) Will Use Its Cash Wisely
Sep 28Sio Gene Therapies EPS beats by $0.12
Jun 09Sio Gene Therapies: Gene Therapies For Neurodegeneration
May 28We Think Sio Gene Therapies (NASDAQ:SIOX) Needs To Drive Business Growth Carefully
May 07Have Insiders Been Buying Sio Gene Therapies, Inc. (NASDAQ:SIOX) Shares?
Mar 04Sio Gene Therapies secures $11.6M from sale of Arvelle Therapeutics
Feb 04What Is The Ownership Structure Like For Sio Gene Therapies, Inc. (NASDAQ:SIOX)?
Jan 28Sio Gene Therapies to sell Arvelle stake to Angelini Pharma
Jan 04Here's Why We're Watching Sio Gene Therapies' (NASDAQ:SIOX) Cash Burn Situation
Dec 24Sio Gene Therapies soars 45% on positive AXO-AAV-GM1 data in nerve cell disorder
Dec 16Did Sio Gene Therapies, Inc. (NASDAQ:SIOX) Insiders Buy Up More Shares?
Nov 19Axovant on go with pivotal study of gene therapy for rare inherited lipid disorders
Nov 09Axovant sees delayed enrollment in Parkinson’s study with gene therapy
Oct 29Financial Position Analysis
Short Term Liabilities: SIOX's short term assets ($47.3M) exceed its short term liabilities ($2.2M).
Long Term Liabilities: SIOX has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: SIOX is debt free.
Reducing Debt: SIOX has no debt compared to 5 years ago when its debt to equity ratio was 49.1%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if SIOX has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if SIOX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.